HOME >> BIOLOGY >> NEWS
BioMed Central applauds Wellcome's leadership on Open Access

Publisher BioMed Central today congratulated the Wellcome Trust on its move to require researchers receiving Wellcome funding to deposit copies of resulting research articles in an Open Access archive. The Trust announced its Open Access policy on 19 May.

"For too long, funders have stood by as the results of scientific and medical research have been handed over to traditional publishers, who have then put those research articles behind subscription barriers," said Matthew Cockerill, Director of Operations at BioMed Central. "Subscription-only access to research does not meet the needs of researchers, funders, or the general public, all of whom benefit from the widest possible access to research findings, which is what Open Access delivers."

"Following on from the National Institutes of Health's similar initiative in the USA, Wellcome's move shows that the funders who spend hundreds of millions of pounds to carry out the research in the first place are no longer prepared to see their research results remain inaccessible."

The Wellcome Trust is the UK's biggest non-governmental funder of biomedical research with an annual spend of 400 million. The recipients of Wellcome's funding produce almost 3500 scientific articles each year. With such a major funding body backing Open Access, it is now expected that other funding bodies around the world will follow suit.

Wellcome's policy specifies that articles must be made freely available within, at most, six months of initial publication, but BioMed Central called on researchers to go further and to make their research accessible immediately on publication, by choosing an Open Access journal."

"Six months is a long time in science with the rapid pace of research, quick access to the latest results is vital. So, the best way for researchers to meet the spirit of the Wellcome policy is to publish in fully Open Access journals, such as those published by BioMed Central."

Publishi
'"/>

Contact: Grace Baynes
press@biomedcentral.com
44-20-7631-9988
BioMed Central
25-May-2005


Page: 1 2

Related biology news :

1. BioMed Central announces new interdisciplinary Biofuels Journal
2. BioMed Central announces winners of first open access research awards
3. BioMed Central launches BMC Systems Biology, a new open access journal
4. Impressive new Impact Factors for BioMed Centrals open-access journals
5. BioMed Central launches Biology Direct
6. BioMed Central welcomes the new National Institutes of Health public access policy
7. BioMed Central announces publishing partnership with The Scientist magazine
8. Woods Hole Research Center scientists study impacts of industrial logging in Central Africa
9. Central and peripheral signals set the circadian liver clock
10. Announcing the launch of Open Access Central
11. EMBL-EBI and collaborators win bid to run UK PubMed Central

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: BioMed Central applauds Wellcome leadership Open Access

(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader in ... is to open in Manhattan, Kansas in early October, 2015. The location of ... research and development through collaboration with researchers from Kansas State University’s College of ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
Cached News: